Ranbaxy Metformin recall in Canada: NDMA above acceptable limits
In plain language
This recall involves RAN-Metformin 850 mg and 500 mg tablets sold in Canada. It's being recalled because it contains N-nitrosodimethylamine (NDMA) above or near acceptable concentration limits. Stop using the product and follow the return steps in the official notice.
What to do
- Stop using the product immediately.
- Check the lot numbers on your product.
- Contact your healthcare professional for advice.
- Return the product as instructed by your pharmacy or healthcare provider.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
RAN-Metformin 850 mg Tablet
Lot: AJZ8005A
RAN-Metformin 500 mg Tablet
Lot: AJY8006A, AJY8007A, AJY8005A, AJY8005B, AJY8008A
Why this matters
Presence of N-nitrosodimethylamine (NDMA) above acceptable limits
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
- 2
Check the lot number
Lot numbers identify specific production batches.
Affected lots: AJY8006A, AJY8007A, AJY8005A, AJY8005B, AJY8008A, AJZ8005A
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
Presence of N-nitrosodimethylamine (NDMA) above acceptable limits
What should consumers do?
Stop using the product immediately. Check the lot numbers on your product. Contact your healthcare professional for advice. Return the product as instructed by your pharmacy or healthcare provider.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Presence of N-nitrosodimethylamine (NDMA) above acceptable limits
When was this product recalled?
This product was recalled on February 26, 2020.
Is the Ranbaxy brand affected by this recall?
Yes, Ranbaxy products are affected by this recall. This recall involves RAN-Metformin 850 mg and 500 mg tablets sold in Canada. It's being recalled because it contains N-nitrosodimethylamine (NDMA) above or near acceptable concentration limits. Stop using the product and follow the return steps in the official notice.